[1] Patel KD, Vora HH, Trivedi TI, Patel JB, Pandya SJ, Jetly DH, et al. Transcriptome profiling and pathway analysis in squamous cell carcinoma of buccal mucosa. Exp Mol Pathol. 2020:104378.
[2] Shi H, Sun H, Li J, Bai Z, Wu J, Li X, et al. Systematic analysis of lncRNA and microRNA dynamic features reveals diagnostic and prognostic biomarkers of myocardial infarction. Aging (Albany NY). 2020;12.
[3] Xu J, Lu Y, Liu Q, Xia A, Zhao J, Xu X, et al. Long noncoding RNA GMAN promotes hepatocellular carcinoma progression by interacting with eIF4B. Cancer Lett. 2019;473:1-12.
[4] Zheng Y, Nie P, Xu S. Long noncoding RNA linc00467 plays an oncogenic role in hepatocellular carcinoma by regulating the miR-18a-5p/NEDD9 axis. J Cell Biochem. 2020.
[5] Chen Q, Fu L. Upregulation of long non-coding RNA ROR1-AS1 promotes cell growth and migration in bladder cancer by regulation of miR-504. PLoS One. 2020;15:e0227568.
[6] Gao M, Fu J, Wang Y. The lncRNA FAL1 protects against hypoxia-reoxygenation- induced brain endothelial damages through regulating PAK1. J Bioenerg Biomembr. 2020.
[7] Song M, Zhong A, Yang J, He J, Cheng S, Zeng J, et al. Large-scale analyses identify a cluster of novel long noncoding RNAs as potential competitive endogenous RNAs in progression of hepatocellular carcinoma. Aging (Albany NY). 2019;11:10422-53.
[8] Wang S, Li G. LncRNA XIST inhibits ovarian cancer cell growth and metastasis via regulating miR-150-5p/PDCD4 signaling pathway. Naunyn Schmiedebergs Arch Pharmacol. 2020.
[9] Yang X, Xin N, Qu HJ, Wei L, Han Z. Long Non-Coding RNA TUG1 facilitates Cell Ovarian Cancer Progression through Targeting MiR-29b-3p/MDM2 Axis. Anat Rec (Hoboken). 2020.
[10] Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene. 2007;26:851-8.
[11] Gabory A, Ripoche M-A, Yoshimizu T, Dandolo L. The <i>H19</i> gene: regulation and function of a non-coding RNA.113:188-93.
[12] Matouk IJ, Abbasi I, Hochberg A, Galun E, Dweik H, Akkawi M. Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis. European Journal of Gastroenterology & Hepatology.21:688-92.
[13] Tsang WP, Wong TWL, Cheung AHH, Co CNN, Kwok TT. Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR. RNA. 2007;13:890-8.
[14] Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer.30:4750-6.
[15] Braconi C, Huang N, Patel T. MicroRNA‐dependent regulation of DNA methyltransferase‐1 and tumor suppressor gene expression by interleukin‐6 in human malignant cholangiocytes. Hepatology. 2010;51.
[16] Zeng B, Lin Z, Ye H, Cheng D, Zhang G, Zhou J, et al. Upregulation of LncDQ is Associated with Poor Prognosis and Promotes Tumor Progression via Epigenetic Regulation of the EMT Pathway in HCC. Cell Physiol Biochem. 2018;46:1122-33.
[17] Zou RC, Shi ZT, Xiao SF, Ke Y, Tang HR, Wu TG, et al. Co-expression analysis and ceRNA network reveal eight novel potential lncRNA biomarkers in hepatocellular carcinoma. PeerJ. 2019;7:e8101.
[18] Zeng YL, Guo ZY, Su HZ, Zhong FD, Jiang KQ, Yuan GD. Diagnostic and prognostic value of lncRNA cancer susceptibility candidate 9 in hepatocellular carcinoma. World J Gastroenterol. 2019;25:6902-15.
[19] Wang J, Su Z, Lu S, Fu W, Liu Z, Jiang X, et al. LncRNA HOXA-AS2 and its molecular mechanisms in human cancer. Clin Chim Acta. 2018;485:229-33.
[20] Wang F, Yang H, Deng Z, Su Y, Fang Q, Yin Z. HOX Antisense lincRNA HOXA-AS2 Promotes Tumorigenesis of Hepatocellular Carcinoma. Cell Physiol Biochem. 2016;40:287-96.
[21] Li X, Zhao Q, Qi J, Wang W, Zhang D, Li Z, et al. lncRNA Ftx promotes aerobic glycolysis and tumor progression through the PPARgamma pathway in hepatocellular carcinoma. Int J Oncol. 2018;53:551-66.
[22] Liu F, Yuan JH, Huang JF, Yang F, Wang TT, Ma JZ, et al. Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a. Oncogene. 2016;35:5422-34.
[23] Liu Z, Dou C, Yao B, Xu M, Ding L, Wang Y, et al. Ftx non coding RNA-derived miR-545 promotes cell proliferation by targeting RIG-I in hepatocellular carcinoma. Oncotarget. 2016;7:25350-65.
[24] Sheng N, Li Y, Qian R, Li Y. The clinical significance and biological function of lncRNA RGMB-AS1 in hepatocellular carcinoma. Biomed Pharmacother. 2018;98:577-84.
[25] Ni W, Zhang Y, Zhan Z, Ye F, Liang Y, Huang J, et al. A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1. J Hematol Oncol. 2017;10:91.
[26] Li ZB, Han YS, Wei LL, Shi LY, Yi WJ, Chen J, et al. Screening and identification of plasma lncRNAs uc.48+ and NR_105053 as potential novel biomarkers for cured pulmonary tuberculosis. Int J Infect Dis. 2020.
[27] Sheng N, Li Y, Qian R, Li Y. The clinical significance and biological function of lncRNA RGMB-AS1 in hepatocellular carcinoma. Biomedicine & Pharmacotherapy.98:577-84.
[28] Ding CH, Yin C, Chen S-J, Wen L-Z, Ding K, Lei S-J, et al. The HNF1α-regulated lncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1. Molecular Cancer.17:63.
[29] Gentric G, Maillet V, Paradis V, Couton D, L'Hermitte A, Panasyuk G, et al. Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease. J Clin Invest. 2015;125:981-92.
[30] Xie G, Huang Z, Liu Z, Lin Z, Ma L. NCPHLDA: a novel method for human lncRNA-disease association prediction based on network consistency projection. Mol Omics. 2019;15:442-50.